Estimates of the Burden of Group B Streptococcal Disease Worldwide for Pregnant Women, Stillbirths, and Children.

摘要: Background: We aimed to provide the first comprehensive estimates of burden group B Streptococcus (GBS), including invasive disease in pregnant and postpartum women, fetal infection/stillbirth, infants. Intrapartum antibiotic prophylaxis is current mainstay prevention, reducing early-onset infant high-income contexts. Maternal GBS vaccines are development. Methods: For 2015 live births, we used a compartmental model estimate (1) exposure maternal colonization, (2) cases disease, (3) deaths, (4) disabilities. applied incidence or prevalence data infants with presenting neonatal encephalopathy. risk ratios numbers preterm births attributable GBS. Uncertainty was also estimated. Results: Worldwide 2015, estimated 205000 (uncertainty range [UR], 101000-327000) 114000 (UR, 44000-326000) late-onset whom minimum 7000 0-19000) presented There were 90000 36000-169000) deaths <3 months age, and, at least 10000 3000-27000) children disability each year. 33000 13000-52000) 57000 12000-104000) infections/stillbirths. Up 3.5 million may be Africa accounted for 54% 65% all fetal/infant deaths. A vaccine 80% efficacy 90% coverage could prevent 107000 20000-198000) stillbirths Conclusions: Our conservative suggest that leading contributor adverse newborn outcomes, 409000 144000-573000) maternal/fetal/infant 147000 47000-273000) annually. An effective reduce mother, fetus, infant.